There is a high frequency of RAS mutations in MM, including neuroblastoma RAS viral oncogene (NRAS) (17–24% of cases), Kirsten rat sarcoma virus (KRAS) (22–27% of cases), and proto-oncogene BRAF (4–8% of cases, with a higher prevalence in relapsed/refractory MM (RRMM)), indicating that this pathway is critical for MM progression [15,19]. The gene discussed is NRAS; the disease is Miyoshi myopathy.